Zimmer Biomet Holdings, Inc. (ZBH) To Go Ex-Dividend on June 25th

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) declared a quarterly dividend on Friday, May 22nd. Investors of record on Thursday, June 25th will be given a dividend of 0.24 per share by the medical equipment provider on Friday, July 31st. This represents a c) dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th.

Zimmer Biomet has a payout ratio of 11.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Zimmer Biomet to earn $8.91 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $87.29 on Tuesday. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $108.29. The firm has a market capitalization of $16.89 billion, a price-to-earnings ratio of 22.67, a P/E/G ratio of 2.59 and a beta of 0.47. The stock’s 50 day moving average price is $87.13 and its two-hundred day moving average price is $90.05. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the previous year, the company posted $1.81 EPS. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts anticipate that Zimmer Biomet will post 8.49 earnings per share for the current year.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by company insiders.

Institutional Trading of Zimmer Biomet

Several large investors have recently modified their holdings of the stock. DV Equities LLC bought a new stake in Zimmer Biomet during the fourth quarter worth about $25,000. Monetary Solutions Ltd acquired a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet in the 4th quarter valued at about $31,000. Flagship Harbor Advisors LLC bought a new position in Zimmer Biomet in the 4th quarter valued at about $32,000. Finally, Grove Bank & Trust raised its position in shares of Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 328 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.